Alghanem Ashjan, Joharji Hala, Garaween Noureldeen, Alenazi Huda, Alsaleh Nada A, Broering Dieter, Alshagrani Mohammed, Alhassan Fatimah, Albassam Ahmed A, Alsultan Abdullah, Alsmari Abeer
Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia.
Pediatr Neonatol. 2025 Jul;66(4):368-374. doi: 10.1016/j.pedneo.2024.11.001. Epub 2024 Nov 29.
Tacrolimus is an essential immunosuppressive medication in paediatric patients' post-liver transplantation. Achieving tacrolimus target concentration in early post-transplantation is crucial to minimise the risk of acute rejection; however, this is challenging due to inter- and intra-patient variability in tacrolimus metabolism and clearance. Therefore, our study aims to describe tacrolimus trough concentration variability and pharmacokinetics in paediatric post-liver transplantation during the first two weeks post-transplantation.
This retrospective multicentre observational study included paediatric patients post-liver transplantation. Post-operative data was collected within the initial 14 days using electronic health records, including daily tacrolimus doses, measured trough concentrations, graft data, surgical data, and documented acute rejection. Pharmacokinetic analysis was completed using the Monolix software. We used the empirical Bayesian estimates of clearance and volume of distribution for covariate testing to assess possible correlations. We performed a stepwise regression analysis (alpha = 0.05).
Ninety-one paediatric patients were included in the study, with a mean age of 4.1 years (SD = 4.6). The mean graft-to-recipient weight ratio (GRWR) was 3% (SD = 6). The vast majority of the patients received the liver from living donors (n = 84, 92.3%). The average time needed to reach therapeutic concentration was 4.6 (SD = 2.8) days. The initial clearance (Clini) was very low at baseline (0.012 L/h), then increased dramatically to 9.84 L/h at 14 days post-transplantation. The clearance appeared to be time-dependent, and the time needed to reach 50% of maximum clearance was five days post-transplantation. The covariates that significantly affected clearance included bodyweight and aspartate transaminase, while the only significant covariate for volume of distribution was bodyweight.
Tacrolimus is a drug with high intra- and interindividual variability, making dosing challenging in the paediatric liver transplantation population. Prospective studies with more intensive sampling are needed to address the time-dependent changes in clearance, which will aid in establishing the optimal dosing regimens in this population.
他克莫司是小儿肝移植术后的一种重要免疫抑制药物。在移植后早期达到他克莫司目标浓度对于将急性排斥反应的风险降至最低至关重要;然而,由于他克莫司代谢和清除的个体间及个体内差异,这具有挑战性。因此,我们的研究旨在描述小儿肝移植术后前两周他克莫司谷浓度的变异性和药代动力学。
这项回顾性多中心观察性研究纳入了小儿肝移植患者。术后14天内使用电子健康记录收集数据,包括每日他克莫司剂量、测得的谷浓度、移植物数据、手术数据以及记录的急性排斥反应。使用Monolix软件完成药代动力学分析。我们使用清除率和分布容积的经验贝叶斯估计进行协变量测试以评估可能的相关性。我们进行了逐步回归分析(α = 0.05)。
91名小儿患者纳入研究,平均年龄4.1岁(标准差 = 4.6)。平均移植物与受体体重比(GRWR)为3%(标准差 = 6)。绝大多数患者接受活体供体肝脏(n = 84,92.3%)。达到治疗浓度所需的平均时间为4.6天(标准差 = 2.8)。初始清除率(Clini)在基线时非常低(0.012 L/h),然后在移植后14天急剧增加至9.84 L/h。清除率似乎与时间相关,达到最大清除率50%所需的时间为移植后5天。显著影响清除率的协变量包括体重和天冬氨酸转氨酶,而分布容积唯一的显著协变量是体重。
他克莫司是一种个体内和个体间变异性高的药物,这使得小儿肝移植人群的给药具有挑战性。需要进行更密集采样的前瞻性研究来解决清除率的时间依赖性变化,这将有助于确定该人群中的最佳给药方案。